News

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...
A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...
In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...
For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.
HealthDay News — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study ...
Prescriptions for Mounjaro jabs, to help people lose weight, will be available at GP surgeries in England from today - but ...
By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...